This inventor holds 1 USPTO granted patent. Top assignee: Cambridge Enterprise Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Tony James Wu and a Patent for Pancreatic Cancer Treatment
Introduction
Tony James Wu is an inventor associated with Cambridge, United Kingdom, and Cambridge Enterprise Limited. His patent work addresses a potential therapeutic approach to pancreatic cancer.
Latest Patents
Wu is associated with 1 patent, titled “Treatment and prognosis of pancreatic cancer.” The invention describes using a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate, or solvate of one, to treat pancreatic cancer. It also discusses combining the antagonist with anti-tumour therapies, including chemotherapeutic agents such as gemcitabine, fluorouracil, capecitabine, FOLFIRINOX, and nab-paclitaxel. The patent further describes possible use alongside immuno-oncology agents, such as PD-1 or PD-L1 inhibitors.
Career Highlights
Wu’s listed patent is focused on a targeted approach to pancreatic cancer treatment and prognosis. His company affiliation is Cambridge Enterprise Limited.
Collaborations
The provided information lists Martin Miller and Michael Gill as Wu’s coworkers. It does not specify their roles in the patent or the nature of their collaboration.
Conclusion
Tony James Wu’s patent work explores CCR1 antagonists, alone or in combination with established cancer therapies, as a potential approach to treating pancreatic cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile